Posted by Michael Wonder on 07 Dec 2016
EMA publishes EPAR for Ninlaro
7 December 2016 - The EMA has published a EPAR for Takeda's proteasome inhibitor.
The European Commission approved Ninlaro (ixazomib citrate) on 21 November 2016 for use in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Ninlaro will be subjected to additional monitoring by the EMA.
